{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:24:59Z","timestamp":1793330699051,"version":"4.5.0"},"reference-count":63,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T00:00:00Z","timestamp":1637020800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Materia Prima"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,6,24]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background and Aims<\/jats:title><jats:p>Filgotinib is a small molecule that selectively inhibits Janus kinase [JAK] type 1. It is already approved for the treatment of rheumatoid arthritis and is being evaluated for the management of patients with moderate to severe ulcerative colitis [UC]. The purpose of this review is to provide an overview of the currently available data on filgotinib and to define how to position this new drug in the treatment algorithm of patients with UC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The Pubmed, Embase and Scopus databases were searched up to June 25, 2021 in order to identify studies reporting efficacy and safety data of filgotinib in patients with UC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Data from a phase III study enrolling UC patients with moderate to severe disease show that filgotinib is effective with a reassuring safety profile. Filgotinib treatment is not associated with a greater risk of thrombosis and herpes zoster infections compared to other JAK inhibitors. However, animal studies reported impaired spermatogenesis and histopathological effects on male reproductive organs, making it necessary to deepen this aspect in dedicated human studies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Filgotinib is an effective and safe drug for treatment of both biologic-naive and biologic-experienced patients with moderate to severe UC and may soon be available.<\/jats:p><\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjab206","type":"journal-article","created":{"date-parts":[[2021,11,12]],"date-time":"2021-11-12T20:11:29Z","timestamp":1636747889000},"page":"835-844","source":"Crossref","is-referenced-by-count":36,"title":["Positioning Filgotinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis"],"prefix":"10.1093","volume":"16","author":[{"given":"Ferdinando","family":"D\u2019Amico","sequence":"first","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University , Pieve Emanuele, Milan , Italy"},{"name":"Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele and Vita-Salute San Raffaele University , Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2634-9668","authenticated-orcid":false,"given":"Fernando","family":"Magro","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Centro Hospitalar S\u00e3o Jo\u00e3o , Porto , Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Peyrin-Biroulet","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Inserm NGERE U1256, University Hospital of Nancy, University of Lorraine , Vandoeuvre-l\u00e8s-Nancy , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio","family":"Danese","sequence":"additional","affiliation":[{"name":"Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele and Vita-Salute San Raffaele University , Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,11,16]]},"reference":[{"key":"2022062411305723400_CIT0001","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis","volume":"389","author":"Ungaro","year":"2017","journal-title":"Lancet Lond Engl"},{"key":"2022062411305723400_CIT0002","first-page":"1280","article-title":"Positioning therapies in ulcerative colitis","volume":"18","author":"Danese","year":"2020","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"},{"key":"2022062411305723400_CIT0003","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/ecco-jcc\/jjy004","article-title":"Primary non-response to tumor necrosis factor antagonists is associated with inferior response to second-line biologics in patients with inflammatory bowel diseases: a systematic review and meta-analysis","volume":"12","author":"Singh","year":"2018","journal-title":"J Crohns Colitis"},{"key":"2022062411305723400_CIT0004","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.coph.2020.10.015","article-title":"New drugs in the pipeline for the treatment of inflammatory bowel diseases: what is coming?","volume":"55","author":"D\u2019Amico","year":"2020","journal-title":"Curr Opin Pharmacol"},{"key":"2022062411305723400_CIT0005","doi-asserted-by":"crossref","first-page":"1756284819848631","DOI":"10.1177\/1756284819848631","article-title":"Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience","volume":"12","author":"D\u2019Amico","year":"2019","journal-title":"Ther Adv Gastroenterol"},{"key":"2022062411305723400_CIT0006","first-page":"2106","article-title":"Positioning tofacitinib in the treatment algorithm of moderate to severe ulcerative colitis","volume":"24","author":"Danese","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"2022062411305723400_CIT0007","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1136\/gutjnl-2019-318448","article-title":"JAK selectivity for inflammatory bowel disease treatment: does it clinically matter?","volume":"68","author":"Danese","year":"2019","journal-title":"Gut"},{"key":"2022062411305723400_CIT0008","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41575-020-0273-0","article-title":"JAK-STAT pathway targeting for the treatment of inflammatory bowel disease","volume":"17","author":"Salas","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2022062411305723400_CIT0009","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med"},{"key":"2022062411305723400_CIT0010","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/apt.15555","article-title":"Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open","volume":"51","author":"Sands","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"2022062411305723400_CIT0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2020.10.038","article-title":"Efficacy and safety of extended induction with tofacitinib for the treatment of ulcerative colitis","author":"Sandborn","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2022062411305723400_CIT0012","article-title":"Maintenance of remission with tofacitinib therapy in patients with ulcerative colitis","author":"Colombel","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2022062411305723400_CIT0013","first-page":"123","article-title":"Tofacitinib treatment is associated with modest and reversible increases in serum lipids in patients with ulcerative colitis","volume":"18","author":"Sands","year":"2020","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"},{"key":"2022062411305723400_CIT0014","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1111\/apt.15514","article-title":"Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme","volume":"50","author":"Sandborn","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"2022062411305723400_CIT0015","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/ecco-jcc\/jjaa233","article-title":"Tofacitinib for the treatment of ulcerative colitis: analysis of infection rates from the ulcerative colitis clinical programme","volume":"15","author":"Winthrop","year":"2021","journal-title":"J Crohns Colitis"},{"key":"2022062411305723400_CIT0016","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1136\/annrheumdis-2020-219012","article-title":"JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib","volume":"80","author":"Traves","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2022062411305723400_CIT0017","author":"Czarska-thorley"},{"key":"2022062411305723400_CIT0018","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0140-6736(16)32537-5","article-title":"Clinical remission in patients with moderate-to-severe Crohn\u2019s disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial","volume":"389","author":"Vermeire","year":"2017","journal-title":"Lancet"},{"key":"2022062411305723400_CIT0019","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1007\/s40265-020-01439-0","article-title":"Filgotinib: first approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"2022062411305723400_CIT0020","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/cpdd.755","article-title":"Filgotinib, a JAK1 inhibitor, has no effect on QT interval in healthy subjects","volume":"9","author":"Anderson","year":"2020","journal-title":"Clin Pharmacol Drug Dev"},{"key":"2022062411305723400_CIT0021","doi-asserted-by":"crossref","first-page":"38","DOI":"10.2174\/1872312810666151223103353","article-title":"Clinical confirmation that the selective JAK1 inhibitor filgotinib (GLPG0634) has a low liability for drug-drug interactions","volume":"10","author":"Namour","year":"2016","journal-title":"Drug Metab Lett"},{"key":"2022062411305723400_CIT0022","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/cpdd.870","article-title":"Lack of drug\u2013drug interaction between filgotinib, a selective jak1 inhibitor, and oral hormonal contraceptives levonorgestrel\/ethinyl estradiol in healthy volunteers","volume":"10","author":"Begley","year":"2021","journal-title":"Clin Pharmacol Drug Dev"},{"key":"2022062411305723400_CIT0023","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1136\/annrheumdis-2021-eular.1685","article-title":"Evaluation of the effect of filgotinib on the pharmacokinetics of rosuvastatin, atorvastatin, and pravastatin","volume":"80","author":"Anderson","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2022062411305723400_CIT0024","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1136\/annrheumdis-2021-eular.933","article-title":"Concomitant use of statins in filgotinib-treated patients with rheumatoid arthritis","volume":"80","author":"Taylor","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2022062411305723400_CIT0025","article-title":"Efficacy and safety of filgotinib as induction therapy for patients with moderately to severely active ulcerative colitis: results from the phase 2b\/3 selection study","author":"Anon","journal-title":"Journal of the Canadian Association of Gastroenterology | Oxford Academic"},{"key":"2022062411305723400_CIT0026","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/jcag\/gwab002.016","article-title":"Efficacy and safety of filgotinib as maintenance therapy for patients with moderately to severely active ulcerative colitis: results from the phase 2b\/3 selection study","volume":"4","author":"Peyrin-Biroulet","year":"2021","journal-title":"J Can Assoc Gastroenterol"},{"issue":"10292","key":"2022062411305723400_CIT0027","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/S0140-6736(21)00666-8","article-title":"Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b\/3 double-blind, randomised, placebo-controlled trial","volume":"397","author":"Feagan","year":"2021","journal-title":"Lancet"},{"key":"2022062411305723400_CIT0028","first-page":"S","article-title":"Early achievement of partial mayo score remission and ibdq normalization in patients with ulcerative colitis treated with filgotinib in the phase 2b\/3 selection study","volume":"160","author":"Md","year":"2021","journal-title":"Gastroenterology"},{"key":"2022062411305723400_CIT0029","author":"Inc"},{"key":"2022062411305723400_CIT0030","author":"Anon"},{"key":"2022062411305723400_CIT0031","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1016\/S0140-6736(18)32483-8","article-title":"Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Mease","year":"2018","journal-title":"Lancet"},{"key":"2022062411305723400_CIT0032","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1016\/S0140-6736(18)32463-2","article-title":"Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial","volume":"392","author":"van der Heijde","year":"2018","journal-title":"Lancet Lond Engl"},{"key":"2022062411305723400_CIT0033","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1136\/annrheumdis-2016-210104","article-title":"Filgotinib (GLPG0634\/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1)","volume":"76","author":"Westhovens","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2022062411305723400_CIT0034","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1136\/annrheumdis-2016-210105","article-title":"Filgotinib (GLPG0634\/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2)","volume":"76","author":"Kavanaugh","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2022062411305723400_CIT0035","author":"Anon"},{"key":"2022062411305723400_CIT0036","author":"Anon"},{"key":"2022062411305723400_CIT0037","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1001\/jama.2019.9055","article-title":"Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the FINCH 2 randomized clinical trial","volume":"322","author":"Genovese","year":"2019","journal-title":"JAMA"},{"issue":"8","key":"2022062411305723400_CIT0038","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.3899\/jrheum.201183","article-title":"Safety and efficacy of filgotinib: up to 4-year results from an open-label extension study of phase II Rheumatoid Arthritis Programs","volume":"48","author":"Kavanaugh","year":"2021","journal-title":"J Rheumatol"},{"key":"2022062411305723400_CIT0039","author":"Anon"},{"key":"2022062411305723400_CIT0040","article-title":"Galapagos reports primary endpoint for the ongoing filgotinib manta and manta-ray safety studies","author":"Nv","year":"2021","journal-title":"GlobeNewswire News Room"},{"key":"2022062411305723400_CIT0041","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2022062411305723400_CIT0042","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1093\/ecco-jcc\/jjz095","article-title":"Vedolizumab treatment in extra-intestinal manifestations in inflammatory bowel disease: a systematic review","volume":"13","author":"Chateau","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2022062411305723400_CIT0043","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s40265-020-01346-4","article-title":"Safety of new biologics (vedolizumab and ustekinumab) and small molecules (tofacitinib) during pregnancy: a review","volume":"80","author":"Gisbert","year":"2020","journal-title":"Drugs"},{"key":"2022062411305723400_CIT0044","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1053\/j.gastro.2020.11.038","article-title":"Pregnancy and neonatal outcomes after fetal exposure to biologics and thiopurines among women with inflammatory bowel disease","volume":"160","author":"Mahadevan","year":"2021","journal-title":"Gastroenterology"},{"key":"2022062411305723400_CIT0045","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/apt.16192","article-title":"Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicentre cohort study","volume":"53","author":"Wils","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"2022062411305723400_CIT0046","doi-asserted-by":"crossref","first-page":"811","DOI":"10.2147\/PPA.S303279","article-title":"Patient preferences for subcutaneous versus intravenous administration of treatment for chronic immune system disorders: a systematic review","volume":"15","author":"Overton","year":"2021","journal-title":"Patient Prefer Adherence"},{"key":"2022062411305723400_CIT0047","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s10067-020-05226-w","article-title":"Insights into the choice between intravenous infusion and subcutaneous injection: physician and patient characteristics driving treatment in SLE","volume":"40","author":"Bell","year":"2021","journal-title":"Clin Rheumatol"},{"key":"2022062411305723400_CIT0048","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1111\/apt.16050","article-title":"Systematic review with meta-analysis: comparative risk of lymphoma with anti-tumour necrosis factor agents and\/or thiopurines in patients with inflammatory bowel disease","volume":"52","author":"Chupin","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"2022062411305723400_CIT0049","doi-asserted-by":"crossref","first-page":"741","DOI":"10.14309\/ajg.0000000000001058","article-title":"Incidence of acute myeloid leukemia and myelodysplastic syndrome in patients with inflammatory bowel disease and the impact of thiopurines on their risk","volume":"116","author":"Khan","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"2022062411305723400_CIT0050","doi-asserted-by":"crossref","first-page":"1756284820967275","DOI":"10.1177\/1756284820967275","article-title":"Risk of malignancies in patients with inflammatory bowel disease who used thiopurines as compared with other indications: a territory-wide study","volume":"13","author":"Zheng","year":"2020","journal-title":"Therap Adv Gastroenterol"},{"key":"2022062411305723400_CIT0051","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/jcpt.13142","article-title":"Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, filgotinib and peficitinib as monotherapy for active rheumatoid arthritis","volume":"45","author":"Ho Lee","year":"2020","journal-title":"J Clin Pharm Ther"},{"key":"2022062411305723400_CIT0052","article-title":"Comparative study of the efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib versus methotrexate for disease-modifying antirheumatic drug-na\u00efve patients with rheumatoid arthritis","author":"Sung","year":"2020","journal-title":"Z Rheumatol"},{"key":"2022062411305723400_CIT0053","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s00393-020-00750-1","article-title":"Relative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in comparison to adalimumab in patients with active rheumatoid arthritis","volume":"79","author":"Lee","year":"2020","journal-title":"Z Rheumatol"},{"key":"2022062411305723400_CIT0054","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00393-020-00796-1","article-title":"Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in active rheumatoid arthritis refractory to biologic disease-modifying antirheumatic drugs","volume":"80","author":"Lee","year":"2021","journal-title":"Z Rheumatol"},{"key":"2022062411305723400_CIT0055","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1053\/j.gastro.2020.01.001","article-title":"Safety of janus kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: a systematic review and meta-analysis","volume":"158","author":"Olivera","year":"2020","journal-title":"Gastroenterology"},{"key":"2022062411305723400_CIT0056","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/ecco-jcc\/jjaa017","article-title":"JAK inhibitors safety in ulcerative colitis: practical implications","volume":"14","author":"Agrawal","year":"2020","journal-title":"J Crohns Colitis"},{"key":"2022062411305723400_CIT0057","article-title":"Herpes zoster and vaccination strategies in inflammatory bowel diseases: a practical guide","author":"Guillo","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2022062411305723400_CIT0058","author":"FDA"},{"key":"2022062411305723400_CIT0059","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1111\/apt.15719","article-title":"Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn\u2019s disease","volume":"51","author":"Yang","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"2022062411305723400_CIT0060","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/1751-2980.12867","article-title":"The use of combination biological or small molecule therapy in inflammatory bowel disease: A retrospective cohort study","volume":"21","author":"Glassner","year":"2020","journal-title":"J Dig Dis"},{"key":"2022062411305723400_CIT0061","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/annrheumdis-2020-218398","article-title":"Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement","volume":"80","author":"Nash","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2022062411305723400_CIT0062","author":"Anon"},{"key":"2022062411305723400_CIT0063","author":"Anon"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjab206\/43846392\/jjab206.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/16\/5\/835\/44245533\/jjab206.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/16\/5\/835\/44245533\/jjab206.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,12]],"date-time":"2023-11-12T15:31:38Z","timestamp":1699803098000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/16\/5\/835\/6429427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,16]]},"references-count":63,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,11,16]]},"published-print":{"date-parts":[[2022,6,24]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjab206","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,5,1]]},"published":{"date-parts":[[2021,11,16]]}}}